Enlivex Therapeutics Ltd. has released its unaudited financial results for the first quarter ending March 31, 2025. The company reported no revenue for the period, consistent with the same quarter in 2024. The net loss for the quarter was $3.452 million, an improvement from a net loss of $4.140 million in the same period last year. Research and development expenses decreased to $2.550 million from $2.857 million, and general and administrative expenses fell to $954,000 from $1.093 million in the previous year. Enlivex's management and board of directors remain optimistic about the company's financial resources, stating they are sufficient to continue product development for at least the next twelve months. However, the company may seek additional capital within this period. The long-term operational viability of Enlivex is dependent on further financial support and the successful development and revenue generation from its product candidates.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.